The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015–2018

Ran Hu1, Shanshan Peng2, Yuanbao Liu3, Fengyang Tang1, Zhiguo Wang1, Lei Zhang1, Jun Gao1* and Hongxiong Guo1*

Abstract

Objective: Adverse events following immunization is an important factor influencing public trust in vaccination. Publicizing its incidence timely can increase public trust. The aim of this study is to describe the incidence and characteristics of adverse events following immunization in Jiangsu province of China from 2015 to 2018.

Methods: All information of adverse events following immunization (AEFIs) was gained from Jiangsu Province Vaccination Integrated Service Management Information System. The reported AEFI trend was analyzed using Chi-square test.

Results: A total of 77,980 AEFI cases were reported through the AEFI system; Among which, 77,731 were classified as non-serious AEFI cases and 249 were serious AEFI cases. The male to female ratio was 1.31:1, cases less than 7 years old accounted for 97.7%. The total estimated AEFI rate was 62.70/100,000 doses. By severity, 60.75/100,000, 4.46/100,000 and 0.11/100,000 AEFI cases were common vaccine reaction, rare vaccine reaction, and serious rare vaccine reaction, respectively. The top two serious AEFI were thrombocytopenic purpura and febrile. The incidence rates showed the increasing trend and the linear trend of the increasing incidence rates passed the significant test at 0.05 levels.

Conclusion: The sensitivity of AEFI monitoring in Jiangsu Province is increasing and higher than the national average and most countries. The majority of AEFI cases were common adverse reactions, while the serious vaccine reactions caused by vaccines were extremely low. To elevate the sensitivity of AEFI surveillance may reduce the incidence of developing serious AEFI cases.

Keywords: Adverse events following immunization, Incidence of adverse events following immunization, Serious vaccine reaction, Common vaccine reaction, Vaccine, Categories of vaccine reaction

* Correspondence: gaojuncdc@163.com; guohongxiong@jscdc.cn
1Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
Full list of author information is available at the end of the article

© The Author(s). 2021 open access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Immunization is the most effective and cost-effective means of public health intervention [1, 2]. Vaccine do not only prevent vaccinated population from getting agents infection and developing a potentially serious illness, but also protect entire communities by reducing their spread [3, 4]. It has led to the global eradication of smallpox as well as the elimination of poliomyelitis in regions of the world [5]. Due to the low prevalence and incidence of vaccine-preventable diseases, the public attention on adverse events following immunization (AEFI) has being increased in recent years [6]. Especially vaccine hesitancy, which often becomes anti-vaccine movement in some regions, even lead a resurgence of some vaccine-preventable diseases [6, 7].

To maintain a good public trust, many countries established surveillance system on vaccine safety. In mainland of China, a passive AEFI Information System (AEFIIS) was established in 2008 [8, 9], and updated twice in 2015, 2018, respectively. The parent of child often reports the symptoms of their child occurred after vaccination to physicians at vaccination clinic, then physicians report this event to AEFIIS if they confirm that it meets the criteria of AEFI. In addition, when clinicians find these AEFIs, they will contact the public health doctors at vaccination clinic. Public health doctors will report them to AEFIIS. All AEFIs monitoring reports and diagnostic requirements are based on National Regulatory Authority evaluation requirements, which is consistent with WHO requirements. However, the AEFIIS is not enough to meet the requirement from various provinces in China. They built their own information system according to their own requirements, and more specific indications are included in provincial ones compared to the Nation’s. In this system, all reported AEFIs are collected. Nonetheless, little data about the characteristics of AEFI from this system was reported.

Jiangsu province, located in the east of China, is a developed region with an approximate 80 million people. Every year, more than 20 million doses were vaccinated. Jiangsu province has been committed to developing its own vaccine information system (Jiangsu Province Vaccination Integrated Service Management Information System) [10]. In this system, the information included the traceability and batch number of vaccine and ones of all vaccinees were collected. Every year, more than ten thousand AEFIs were documented since 2015. By using the AEFI monitor system and the traceability system, we may obtain more accurate vaccination information in case of AEFI. In this study, we reported the basic characteristics of reported AEFI from Jiangsu provincial AEFIs.

Materials and methods

AEFI data

AEFI case data and vaccination information were gained from Jiangsu Provincial AEFI information management system, which covered all AEFI cases collected from January 1, 2015 to December 31, 2018 and information of 53 vaccines.

The definition of AEFI

AEFIs were classified into adverse event following immunization, vaccine quality, program error, coincidental event and psychogenic reaction. Vaccination-related reactions or events include fever (axillary temperature ≥ 38.6 °C), local redness (diameter > 2.5 cm), local induration (diameter > 2.5 cm), allergic skin rash (including urticaria, maculopapular rash, measles, scarlet fever-like rash), angioedema, anaphylactic shock, allergic laryngeal edema, Henoch schonlein purpura (HSP), thrombocytopenic purpura (TP), local allergic necrosis (Arthus response), febrile seizures, epilepsy, brachial plexus neuritis, polyneuritis, Guillain-Barré syndrome (GBS), Acute disseminated encephalo-myelitis (ADEM), encephalitis and meningitis, encephalopathy, Vaccine-associated paralytic poliomyelitis (VAPP), BCG lymph nodes Inflammation, BCG osteomyelitis, disseminated BCG infection, aseptic abscess, local abscess, lymphangitis and lymphadenitis, cellulitis, systemic purulent infection (poison) Disease, sepsis, sepsis), toxic shock syndrome, syncope, hysteria and suspicion and vaccinations related to other serious AEFI. Severe AEFI is an AEFI that causes death, life-threatening, permanent or significant disability or organ function damage, including allergic laryngeal edema, anaphylactic shock, HSP, TP, arthus response, febrile seizures, epilepsy, brachial plexus neuritis, polyneuritis, GBS, ADEM, encephalopathy, encephalitis and meningitis, VAPP, BCG osteomyelitis, disseminated BCG infection, syncope, toxic shock syndrome, generalized purulent infection [11].

Statistics analysis

The data of AEFI cases in China’s AEFI information management system from 2015 to 2018 were exported to Microsoft Excel for statistical analysis. If two or more vaccines are vaccinated at the same time, the most suspected vaccine will be included in the calculation. Trend test was calculated by χ² with R. In this study, the north area includes Xuzhou, Huai’an, Lianyungang, Suqian, Yancheng, Nantong, Yangzhou, Taizhou; The south area includes Nanjing, Zhenjiang, Changzhou, Wuxi, Suzhou. The incidence rate of an AEFI for a vaccine (100,000 doses) = the number of AEFI reports / the number of vaccinations × 100,000 doses.
Results

The baseline characteristic of AEFI cases

From 2015 to 2018, a total of 77,980 AEFI cases were reported. The average incidence of AEFI is 65.4 per 100,000 doses. Of which, 77,686 were adverse reactions, accounting for 99.62% (72,377 were common vaccine reactions, while 5309 were rare vaccine reactions); 285 were coincidental events (0.37%); 8 were cases of psychogenic reaction (0.009%); 1 was program error (0.001%); no vaccine quality accident was reported. As shown in Table 1, the incidence of AEFI in male was higher than that in female. 97.7% of total AEFI was reported in children less than seven years old, especially in children younger than one year old, which took account for 56.36%. More AEFIs occur between April and September every year. Non-serious AEFI and Serious AEFI shared with the similar baseline characteristics.

Vaccine-specific reporting rate for vaccine adverse events

The highest incidence rates of common vaccine reactions were DTaP-IPV/Hib (251.27/100,000), PPV23 (242.66/100,000) and DTaP (198.58/100,000). The highest incidence rates of rare vaccine reactions were MR (46.76/100,000), MV (46.01/100,000) and PCV7 (24.97/100,000). The highest incidence rates of AEFI were DTaP-IPV/Hib (258.94/100,000), PPV23 (248.98/100,000) and DTaP (204.27/100,000) (as shown in Table 2).

Characteristics of vaccine adverse events cases and its distribution

Common reaction associated with vaccination consists of high fever, redness and swelling in shot site, and scleroma. Of them, high fever takes account for 42.73%, followed by redness and swelling in shot site (38.81%). Abnormal reaction includes allergic reaction, nervous system response, BCG specific reaction, and injection site reaction, and others. Among abnormal reaction, allergic reaction is the major, which accounts for 89.88%. Among allergic reaction, allergic skin rash is the predominant, reaches to 94.05%. Nervous system response and BCG specific reaction reaches to 2.37 and 0.52%, respectively (as shown in Table 3).

People vaccinated against DTaP and DT are more likely to have induration (DTaP, 71.23/100,000; DT, 65.01/100,000), redness and swelling (DTaP, 148.88/100,000; DT, 132.83/100,000). People vaccinated against MR and MPV-A are more likely to have fever (MR, 119.60/100,000; MPV-A, 84.79/100,000). People vaccinated against MR and MMR are more likely to have allergic skin rash (MR, 45.16/100,000; MMR, 6.53/100,000). BCG lymphadenitis is more common, compared to other specific reactions of BCG.

Severity of the vaccine adverse events

As shown in Table 4, from 2015 to 2018, serious AEFI cases reaches to 249. Among them, abnormal reaction takes account for 52.61%, while psychogenic reaction
| Vaccine | Common Vaccine Reaction | No. of cases | proportion(%) | Estimated incidence | No. of cases | proportion(%) | Estimated incidence | AEFI | No. of cases | proportion(%) | Estimated incidence |
|---------|-------------------------|--------------|---------------|---------------------|--------------|---------------|---------------------|------|--------------|---------------|---------------------|
| BCG     |                         | 295          | 0.408         | 7.33                | 346          | 6.521         | 8.60                |      | 658          | 0.84          | 16.35               |
| HepB (CHO) |                   | 116          | 0.160         | 11.48               | 14           | 0.264         | 1.39                |      | 131          | 0.17          | 12.96               |
| HepB (YEAST) |                 | 3787         | 5.234         | 33.10               | 192          | 3.619         | 1.68                |      | 4017         | 5.15          | 35.11               |
| tOPV    |                         | 402          | 0.556         | 6.85                | 54           | 1.018         | 0.92                |      | 464          | 0.60          | 7.91                |
| IPV (Sabin) |                  | 363          | 0.502         | 65.01               | 34           | 0.641         | 6.09                |      | 401          | 0.51          | 71.82               |
| IPV (Salk) |                    | 645          | 0.891         | 25.28               | 70           | 1.319         | 2.74                |      | 736          | 0.94          | 28.84               |
| bOPV    |                         | 917          | 1.267         | 13.52               | 125          | 2.356         | 1.84                |      | 1054         | 1.35          | 15.54               |
| DTaP    |                         | 29,464       | 40.719        | 198.58              | 757          | 14.267        | 5.10                |      | 30,278       | 38.84         | 204.07              |
| IPV  |                         | 5905         | 8.161         | 166.41              | 61           | 1.150         | 1.72                |      | 5974         | 7.66          | 168.35              |
| Tetanus |                         | 1            | 0.001         | 1.30                | 1            | 0.019         | 1.30                |      | 2            | 0.00          | 2.60                |
| MV      |                         | 298          | 0.412         | 126.95              | 108          | 2.035         | 46.01               |      | 410          | 0.53          | 174.67              |
| MR      |                         | 4717         | 6.519         | 121.11              | 1821         | 34.320        | 46.76               |      | 6558         | 8.41          | 168.38              |
| MPV-A   |                         | 7811         | 10.795        | 100.49              | 316          | 5.956         | 4.07                |      | 8153         | 10.46         | 104.89              |
| MPV-AC  |                         | 2776         | 3.836         | 38.18               | 164          | 3.091         | 2.26                |      | 2952         | 3.79          | 40.60               |
| MPV-AC/Hib |                 | 83           | 0.115         | 32.43               | 6            | 0.113         | 2.34                |      | 89           | 0.11          | 34.78               |
| MPV-ACYW135 |                | 64           | 0.088         | 38.60               | 3            | 0.057         | 1.81                |      | 68           | 0.09          | 41.01               |
| JEV-L   |                         | 3754         | 5.188         | 46.34               | 328          | 6.182         | 4.05                |      | 4089         | 5.25          | 50.48               |
| JEV-I   |                         | 80           | 0.111         | 49.35               | 7            | 0.132         | 4.32                |      | 87           | 0.11          | 53.67               |
| HepA-L  |                         | 1            | 0.001         | 0.42                | 0            | 0.000         | 0.00                |      | 1            | 0.00          | 0.42                |
| HepA-I  |                         | 2198         | 3.038         | 28.41               | 136          | 2.563         | 1.76                |      | 2339         | 3.00          | 30.23               |
| HepAB   |                         | 20           | 0.028         | 34.40               | 1            | 0.019         | 1.72                |      | 21           | 0.03          | 36.12               |
| Infv    |                         | 539          | 0.745         | 41.40               | 34           | 0.641         | 2.61                |      | 579          | 0.74          | 44.47               |
| VarV    |                         | 824          | 1.139         | 38.95               | 100          | 1.885         | 4.73                |      | 932          | 1.20          | 44.06               |
| Hib     |                         | 956          | 1.321         | 74.17               | 64           | 1.206         | 4.97                |      | 1020         | 1.31          | 79.13               |
| ORV     |                         | 109          | 0.151         | 27.58               | 7            | 0.132         | 1.77                |      | 117          | 0.15          | 29.61               |
| PPV23   |                         | 845          | 1.168         | 242.66              | 21           | 0.396         | 6.03                |      | 867          | 1.11          | 248.98              |
| PCV7    |                         | 23           | 0.032         | 95.73               | 6            | 0.113         | 24.97               |      | 29           | 0.04          | 120.70              |
| PCV13   |                         | 219          | 0.303         | 127.33              | 16           | 0.302         | 9.30                |      | 236          | 0.30          | 137.21              |
| RabV    |                         | 1037         | 1.433         | 5.11                | 76           | 1.432         | 0.37                |      | 1123         | 1.44          | 5.53                |
| DTaP-Hib |                       | 274          | 0.379         | 169.66              | 12           | 0.226         | 7.43                |      | 286          | 0.37          | 177.09              |
| DTaP-IPV-Hib |              | 1309         | 1.809         | 251.27              | 34           | 0.641         | 6.53                |      | 1349         | 1.73          | 258.94              |
| HepE    |                         | 6            | 0.008         | 29.19               | 0            | 0.000         | 0.00                |      | 6            | 0.01          | 29.19               |
| MPV-AC/Hib |                   | 132          | 0.182         | 51.98               | 13           | 0.245         | 5.12                |      | 145          | 0.19          | 57.10               |
| EV71(Human Diploid) |    | 282          | 0.390         | 34.39               | 40           | 0.754         | 4.88                |      | 328          | 0.42          | 40.01               |
| EV71(Vero) |                   | 249          | 0.344         | 64.83               | 31           | 0.584         | 8.07                |      | 283          | 0.36          | 73.68               |
| B-HPV   |                         | 14           | 0.019         | 9.23                | 3            | 0.057         | 1.98                |      | 18           | 0.02          | 11.87               |
| Q-HPV   |                         | 16           | 0.022         | 10.12               | 4            | 0.075         | 2.53                |      | 21           | 0.03          | 13.28               |
| Total   |                         | 72,359       | 100.000       | 60.68               | 5306         | 100.000       | 4.45                |      | 77,959       | 100.00        | 65.38               |
The reported incidence of AEFI in Jiangsu during 2015–2018 was 69.70/100,000 doses, which is significantly higher than the average AEFI incidence reported in the whole China [11] and the incidence of AEFI reported in other countries [12–16]. According to the 2016 annual report released by the National Center for Immunization Planning, the reported incidence of AEFI in China was 39.01/100,000 doses [11]. In USA, the reported incidence of AEFI reached to 11.4/100,000 doses in 1999–2001 and approximately 12.8/100,000 doses after 2013 [12]. In Australia, an annual AEFI reporting rate of 16.9/100,000 doses was administered in 2018, which was closed to the average annual AEFI reporting rate (13.4/100,000 doses) distributed in Canada for vaccines administered during 2013–2016 [15, 17].

Higher reported incidence of AEFI in Jiangsu Province of China may be contributed partially from the sensitivity of AEFI monitoring system. In Jiangsu province, all potential AEFI cases should be reported with 48 h, and the follow investigation be conducted within the second 48 h, and all questionnaires be uploaded within 72 h. All community doctors were trained periodically, and adverse reaction after vaccination were widely publicized for parents and guardians of children in clinics and society news media. All these endeavors increased the sensitivity of AEFI monitoring system. Especially since 2015, training for community doctors and publicizing the knowledge about vaccination were enforced. Moreover, the monitoring system was updated for many times. Consequently, the sensitivity of monitoring AEFI gradually rose, and the reported AEFI incidence increased at a rate of about 9% since 2015.

Among all reported AEFI cases, the incidence of the severe cases accounted for 0.32% during the four-year period, which was less than the average incidence in the whole China (0.78%, 2015–2016, 11] and those in Australia (16%, 2018, 14] and the United States (7%, 2011–2014, 12]. The difference on the incidence of severe AEFIs between countries partially was caused by the different definition of severe AEFI in various countries. However, the incidence of severe AEFIs may be reduced by other factors such as local medical resources, the measures associated with vaccination, the sensitivity of monitoring system on AEFI, even economic level. Jiangsu province, as one of the most developed provinces in China, has higher public health service, medical resource, communication system. Furthermore, all people were required to stay for another 30 min after they were vaccinated in Jiangsu province, all vaccination clinics qualify to administrate this reaction. As we knew, the immediate hypersensitivity is one of severe AEFIs [18]. Moreover, higher sensitivity on monitoring AEFI may prevent many AEFI cases from developing severe ones.

### Table 3 The symptoms and signs of AEFIs from 2015 to 2018 in Jiangsu, China

| AEFI                                               | Total |
|---------------------------------------------------|-------|
| Common reaction                                   |       |
| High fever                                        | 34,762|
| Redness and swelling                              | 31,576|
| scleroma                                          | 15,013|
| Abnormal reaction                                 |       |
| Allergic reaction                                 |       |
| Anaphylactic shock                                | 2     |
| Allergic purpura                                  | 12    |
| Edema of larynx                                   | 1     |
| Arthus reaction                                   | 2     |
| Angioedema                                        | 48    |
| Thrombocytopenic purpura                          | 49    |
| Allergic skin rash                                | 4060  |
| Other allergic reactions                           | 143   |
| Nervous system response                           |       |
| Febrile convulsion                                | 17    |
| Acute disseminated encephalomyelitis              | 2     |
| epilepsy                                          | 2     |
| encephalopathy                                    | 1     |
| Vaccine associated paralytic poliomyelitis        | 1     |
| Other nervous system reactions                     | 2     |
| BCG specific reaction                             |       |
| BCG lymphadenitis                                 | 94    |
| Systemic disseminated BCG infection               | 2     |
| BCG local abscess                                 | 14    |
| Other reactions of BCG                            | 4     |
| Injection site reaction                           |       |
| sterile abscess                                   | 34    |
| Other local reactions                             | 6     |
| Others                                            | 307   |
| Total                                             | 86,154|

The main abnormal reaction is allergic reaction thrombocytopenic purpura which reaches to 53, followed by febrile convulsion for 26 and Henoch Schonlein purpura for 14.

### The trend of AEFI over year

From 2015 to 2018, AEFI incidence per 100,000 doses in 2015, 2016, 2017, and 2018 was 55.88, 63.45, 68.49, and 74.38, respectively (as shown in Fig. 1). The reported AEFI incidence has being increased at a rate of nearly 9% since 2015.
More than that, 0.03% death cases of AEFIs are lower in Jiangsu province than in the whole China (0.07%, 2015–2016) and Australia (0.16%, 2014–2015). Of the 26 deaths, 24 were eventually diagnosed as coincidental. Coincidental serious diseases were the main causes of death, which was similar to the monitoring situation of death cases in the whole China and the United States vaccine adverse event reporting system (VAERS) from 1997 to 2013 [19].

The incidence and symptom of AEFIs are associated with vaccines’ complements. For example, the incidence of AEFI is higher in population vaccinated with DTaP, DT and MPV-A vaccines than others [20, 21]. MPV-A, MR and JEV-L have been reported to have a higher incidence of inducing fever [22], while DTaP, DT and other DTaP-related vaccines have been reported to have a higher incidence of causing local redness and induration [23]. MPCV-A is easier to induce fever than MPCV-AC.

### Table 4 The distribution of various severe AEFIs reported from 2015 to 2018 in Jiangsu, China

| Final clinical diagnosis                         | Abnormal reaction | Coincidence | Psychogenic reaction | Total |
|-------------------------------------------------|-------------------|-------------|----------------------|-------|
| Febrile convulsion                              | 26                | 24          | 0                    | 50    |
| Allergic reaction - anaphylactic shock          | 8                 | 0           | 0                    | 8     |
| Allergic reaction - Henoch Schonlein purpura   | 14                | 7           | 0                    | 21    |
| Allergic reaction thrombocytopenic purpura     | 53                | 24          | 0                    | 77    |
| Allergic reaction - laryngosis edema           | 2                 | 1           | 0                    | 3     |
| Allergic reactions - other allergic reactions   | 0                 | 2           | 0                    | 2     |
| Guillain-Barre Syndrome                         | 1                 | 1           | 0                    | 2     |
| Epilepsy                                        | 2                 | 7           | 0                    | 9     |
| Encephalopathy                                  | 1                 | 2           | 0                    | 3     |
| Encephalitis and meningitis                     | 1                 | 2           | 0                    | 3     |
| Vaccine associated paralytic poliomyelitis      | 3                 | 0           | 0                    | 3     |
| Systemic BCG infection                          | 2                 | 0           | 0                    | 2     |
| Systemic suppurative infection - toxemia        | 0                 | 1           | 0                    | 1     |
| Systemic suppurative infection sepsis           | 0                 | 3           | 0                    | 3     |
| Syncope                                         | 1                 | 1           | 3                    | 5     |
| Acute disseminated encephalomyelitis            | 4                 | 1           | 0                    | 5     |
| Other                                           | 13                | 38          | 1                    | 52    |
| Total                                           | 131               | 114         | 4                    | 249   |

![Fig. 1 The trend of AEFIs incidence from 2015 to 2018 in Jiangsu, China](image-url)
Seven cases of anaphylactic shock linked to AEFI were reported from 2015 to 2018 with an incidence of 0.006/100,000 doses, 2 of them were caused by immunization program vaccine (DTaP and MR), and 5 were rendered by PPV23 and rabies vaccine. Among AEFIs, anaphylactic shock is often caused by the residual ovalbumin or gelatin in vaccine gradients. The residual gradients in vaccine products were influenced by manufacture process. In China, the incidence of anaphylactic shock in AEFIs is between 0.005/100,000 doses – 0.08/100,000 doses. It is higher than that in USA with an incidence from 0.02/100,000 doses to 0.13/100,000 doses [24, 25]. This difference may be varied from the different process in various countries.

There are some limitations in the study. Firstly, the actual number of inoculants and the reported number of inoculants may not be completely consistent. In addition to obtaining the report of the number of inoculants from the system, we verified the actual number of inoculants from the aspects of birth population, floating population and vaccination rate to ensure the accuracy of the number of inoculants may not be completely consistent. Secondly, differences in AEFI monitoring reports, disease diagnosis abilities and investigation abilities among different regions definitely exist. We do our best to ensure that all monitors are trained in standardization and can ensure the accuracy of the data.

Conclusion

Although the incidence of AEFI in Jiangsu province increased from 2015 to 2018, common vaccine reactions were predominant while the incidence rates of severe abnormal reactions such as anaphylactic shock and VAPP were very rare. The continuous improving sensitivity in monitoring AEFIs together with standardized training in community doctors may be useful to decrease the incidence of developing severe AEFIs.

Abbreviations

VAPP: Vaccine-associated paralytic poliomyelitis; AEFI: Adverse events following immunization; AEFIIS: Adverse events following immunization information system

Acknowledgments

We thank all staff who are involved in surveillance on AEFI in Jiangsu province.

Authors’ contributions

RH, JG, YL, LZ, FT, and ZW collected and reviewed data. RH, SP, JG, and HG analyzed data and interpret results. RH, JG, and HG edited manuscript. All authors read and approved the final manuscript.

Funding

This project was supported partly by the project funded by Jiangsu Provincial High-Level Talents Programs in Health (LGY2016021).

Availability of data and materials

The datasets used in this study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Author details

1. Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. 2. Department of Hepatology, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China.

Received: 12 January 2021 Accepted: 22 June 2021

Published online: 07 July 2021

References

1. Lee JS, Louren OJ, Gupta S, Farlow A. A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia. VACCINE. 2018;36(7):2346–55.
2. Giersing BK, Karzon RA, Vekemans J, Kaskow DC, Moorthy VS. Meeting report: WHO consultation on respiratory syncytial virus (RSV) vaccine development, Geneva, 25–26 April 2016. Vaccine. 2019;37(50):7355–62.
3. Saber Y, Philippe G, Assiri AM, Gessner BD, Badriah A. Prevention of meningococcal disease at mass gatherings: lessons from the Hajj and Umrah. Vaccine. 2018;36(1):4603–9.
4. Adams LG, Khare S, Lawhon SD, Rossetti CA, Lewin HA, Lipton MS, et al. Enhancing the role of veterinary vaccines reducing zoonotic diseases of humans: linking systems biology with vaccine development. Vaccine. 2011;29(41):7197–206.
5. Kew NNOM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010;172(11):1213–29.
6. Gidudu JF, Shaum A, Habersaat K, Wilhelm E, Wooding J, Mast E, et al. An approach for preparing and responding to adverse events following immunization reported after hepatitis B vaccine birth dose administration. Vaccine. 2020;38(49):7728–40.
7. Bonaldo G, Vaccheri A, D’Annibali O, Motola D. Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017. Brit J Clin Pharmaco. 2019;85(3):634–43.
8. Wen-Di WU, Liu DW, Bing-Bing WU. Analysis on the Surveillance of Adverse Events Following Immunization in China,2007-2008. Chin J Vaccines Immunization. 2009;15(6):481–90.
9. Surveillance of adverse events following immunization in China: Past, present, and future. Vaccine. 2015;33(32):4041–4046.
10. Guodong K, Wang Z, Hu R, Yu J, Fenyang T. Construction and application of the Jiangsu Province vaccination integrated service management information system based on a cloud platform. Chin J Vaccines and Immunization. 2020;26(04):94–8.
11. Xu D, Keli L, Wendi W, Jiakai Y, Zhaizhai J, Jinghnan Z, et al. Adverse events following immunization in China. Chin J Vaccines Immunization. 2018;24(3):299–309.
12. Shimabukuro TT, Nguyen M, Martin D, Destefano F. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33(36):4398–405.
13. Dey A, Wang H, Quinn H, Hiam R, Macartney K. Surveillance of adverse events following immunisation in Australia annual report, 2017. Commun Dis Intell. 2018;2019;43(3):1–28.
14. Dey A, Wang H, Quinn H, Pillsbury A, Glover C, Hickie M, et al. Surveillance of adverse events following immunisation in Australia: annual report, 2018. Commun Dis Intell. 2020;44:1–28.
15. Ahmadipour W, Fréchette C, Anyotyi J. Vaccine safety surveillance in Canada: Reports to CAEFSS, 2013–2016. Can Commun Dis Rep. 2018;44(9):206–14.
16. Jyoti J, Manoja K, Das D, Polpakara S, Aneja M. Vaccine safety and surveillance for adverse events following immunization (AEFI) in India. Indian J Pediatr. 2018;85(2):139–48.
17. Dey A, Wang H, Quinn H, Pillsbury A, Macartney K. Surveillance of adverse events following immunisation in Australia: annual report, 2019. Commun Dis Intell. 2020;44:1–30.
18. Freitas DRC, Moura E, Araújo G, Cardoso A, Scheidt P, Ferraz E, et al. Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil. Vaccine. 2013;31(6):950–4. https://doi.org/10.1016/j.vaccine.2012.11.095.
19. Wendi W, Dawei L, J. P, Nuorti K, Li D. Deaths reported to national surveillance for adverse events following immunization in China, 2010–2015. Vaccine. 2019;37(9):1182–7.
20. Yue CY, Ke-Li LL, Guo B. Analysis on pilot surveillance counties of adverse events following immunization in China. Chin J Vaccines Immunization. 2012;18(3):246–51.
21. Geier DA, Geier MR. Clinical implications of endotoxin concentrations in vaccines. Ann Pharmacother. 2002;36(5):776–80. https://doi.org/10.1345/aph.1A410.
22. Esteghamati A, Keshhtkar A, Heshmat R, Gouya MM, Mahoney F. Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran. Arch Iran Med. 2011;14(2):91–5.
23. Cerpa-Cruz S, Paredes-Casillas P, Landeros Navarro E, Bernard-Medina AG, Martínez-Bonilla G, Gutiérrez-Ureña S. Adverse events following immunization with vaccines containing adjuvants. Immunol Res. 2013;56(2–3):299–303. https://doi.org/10.1007/s12026-013-8400-4.
24. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the vaccine adverse event reporting system (VAERS) safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33(36):4398–405.
25. Mcneill MM, Weintraub ES, Duffy J, Sukumar L, Jacobson SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868–78.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.